Albany Molecular Research
ALBANY MOLECULAR RESEARCH INC (Form: 10-Q, Received: 08/09/2012 17:25:06)

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended June 30, 2012

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from               to

 

Commission file number: 0-25323

 

ALBANY MOLECULAR RESEARCH, INC.

(Exact name of registrant as specified in its charter)

DELAWARE   14-1742717
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

21 Corporate Circle

PO Box 15098

Albany, New York 12212-5098  

(Address of principal executive offices)

 

(518) 512-2000 

(Registrant’s telephone number, including area code)

N/A

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes    x   No    ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes    x   No    ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨   Accelerated filer x  
Non-accelerated filer ¨   Smaller reporting company ¨  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes    o   No    x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at July 31, 2012  
Common Stock, $.01 par value   30,805,968 excluding treasury shares of 5,411,372  

 

 

 

 
 

 

ALBANY MOLECULAR RESEARCH, INC.

 

INDEX

Part I.   Financial Information   3
             
    Item 1.   Condensed Consolidated Financial Statements (Unaudited)   3
             
        Condensed Consolidated Statements of Operations   3
        Condensed Consolidated Statements of Comprehensive Income (Loss)   4
        Condensed Consolidated Balance Sheets   5
        Condensed Consolidated Statements of Cash Flows   6
        Notes to Condensed Consolidated Financial Statements   7
             
    Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations   17
             
    Item 3.   Quantitative and Qualitative Disclosures About Market Risk   25
             
    Item 4.   Controls and Procedures   25
             
Part II.   Other Information   26
             
    Item 1.   Legal Proceedings   25
             
    Item 1A.   Risk Factors   26
             
    Item 6.   Exhibits   26
             
Signatures       26
             
Exhibit Index        

 

2
 

 

PART I — FINANCIAL INFORMATION

 

Item 1.  Condensed Consolidated Financial Statements (Unaudited)

 

Albany Molecular Research, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

 

    Three Months Ended     Six Months Ended  
(Dollars in thousands, except for per share data)   June 30, 2012     June 30, 2011     June 30, 2012     June 30, 2011  
                         
Contract revenue   $ 42,390     $ 43,497     $ 85,100     $ 86,428  
Recurring royalties     7,529       7,380       18,514       21,396  
Milestone revenue     90       3,000       90       3,000  
Total revenue     50,009       53,877       103,704       110,824  
                                 
Cost of contract revenue     36,251       41,186       75,921       82,728  
Technology incentive award     753       791       1,852       2,193  
Research and development     231       1,910       604       4,514  
Selling, general and administrative     9,841       9,786       19,687       21,198  
Restructuring charges     1,439             2,127       951  
Impairment charges                 3,967        
Arbitration charge                       127  
Total operating expenses     48,515       53,673       104,158       111,711  
                                 
Income (loss) from operations     1,494       204       (454 )     (887 )
                                 
Interest expense, net     (113 )     (83 )     (255 )     (122 )
Other income (expense), net     136       (453 )     (656 )     (414 )
                                 
Income (loss) before income taxes     1,517       (332 )     (1,365 )     (1,423 )
                                 
Income tax expense     1,260       236       2,185       612  
                                 
Net income (loss)   $ 257     $ (568 )   $ (3,550 )   $ (2,035 )
                                 
Basic income (loss) per share   $ 0.01     $ (0.02 )   $ (0.12 )   $ (0.07 )
                                 
Diluted income (loss) per share   $ 0.01     $ (0.02 )   $ (0.12 )   $ (0.07 )

 

See notes to unaudited condensed consolidated financial statements.

 

3
 

 

Albany Molecular Research, Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(unaudited)

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2012     2011     2012     2011  
Net income (loss)   $ 257     $ (568 )   $ (3,550 )   $ (2,035 )
Unrealized loss on marketable securities, net of taxes     -       (20 )     (1 )     (19 )
Foreign currency translation (loss) gain     (1,294 )     678       722       3,420  
Net actuarial gain of pension and postretirement benefits     113       74       249       146  
Total comprehensive (loss) income   $ (924 )   $ 164     $ (2,580 )   $ 1,512  

 

See notes to unaudited condensed consolidated financial statements.

 

4
 

 

Albany Molecular Research, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

 

(Dollars and shares in thousands, except for per share data)   June 30, 
2012
    December 31,
2011
 
Assets                
Current assets:                
Cash and cash equivalents — unrestricted   $ 13,395     $ 19,984  
Accounts receivable, net     35,258       30,437  
Royalty income receivable     7,005       6,819  
Income taxes receivable     3,556       3,407  
Inventory     35,879       26,004  
Prepaid expenses and other current assets     10,849       10,130  
Deferred income taxes     3,319       3,779  
Total current assets     109,261       100,560  
                 
Property and equipment, net     142,187       149,796  
                 
Restricted cash     5,000        
Intangible assets and patents, net     3,062       2,976  
Equity investment in unconsolidated affiliates     956       956  
Deferred income taxes     5,563       7,373  
Other assets     1,350       1,406  
Total assets   $ 267,379     $ 263,067  
                 
Liabilities and Stockholders’ Equity                
Current liabilities:                
Accounts payable and accrued expenses   $ 27,979     $ 23,175  
Arbitration reserve     3,400       4,082  
Deferred revenue and licensing fees     7,170       6,464  
Accrued pension benefits     871       1,416  
Current installments of long-term debt     418       2,839  
Total current liabilities     39,838       37,976  
                 
Long-term liabilities:                
Long-term debt, excluding current installments     7,587       3,003  
Deferred licensing fees     3,571       4,286  
Deferred income taxes     829       733  
Pension and postretirement benefits     9,168       9,047  
Other long-term liabilities     1,385       1,588  
Total liabilities     62,378       56,633  
                 
Commitments and contingencies                
                 
Stockholders’ equity:                
Common stock, $0.01 par value, 50,000 shares authorized, 36,223 shares issued as of  June 30, 2012, and 36,016 shares issued as of December 31, 2011     362       360  
Additional paid-in capital     207,219       206,074  
Retained earnings     75,404       78,954  
Accumulated other comprehensive loss, net     (11,096 )     (12,066 )
      271,889       273,322  
Less, treasury shares at cost, 5,411 shares as of June 30, 2012 and December 31, 2011     (66,888 )     (66,888 )
Total stockholders’ equity     205,001       206,434  
Total liabilities and stockholders’ equity   $ 267,379     $ 263,067  

 

See notes to unaudited condensed consolidated financial statements.

 

5
 

 

Albany Molecular Research, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

 

    Six Months Ended  
(Dollars in thousands)   June 30, 2012     June 30, 2011  
             
Operating activities                
Net loss   $ (3,550 )   $ (2,035 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     8,900       8,827  
Deferred income taxes     1,961       3,041  
Impairment and loss on disposal of property, plant and equipment     3,967       3  
Stock-based compensation expense     1,066       745  
Provision for (recoveries of) bad debt     148       (89 )
Loss on disposal of property, plant and equipment     102        
(Recoveries of) provision for inventory reserves     (214 )     964  
Changes in assets and liabilities:                
Accounts receivable     (4,969 )     2,756  
Royalty income receivable     (186 )     (432 )
Inventory     (9,661 )     (3,587 )
Prepaid expenses and other assets     (1,391 )     922  
Income taxes receivable     (149 )     (2,359 )
Accounts payable and accrued expenses     4,011       (6,755 )
Deferred revenue and licensing fees     (9 )     (5,688 )
Pension and postretirement benefits     (41 )     4  
Other long-term liabilities     (92 )     (79 )
Net cash used in operating activities     (107 )     (3,762 )
                 
Investing activities                
Purchases of investment securities           (1,347 )
Proceeds from sales and maturities of investment securities     213       11,772  
Purchase of property, plant and equipment     (4,397 )     (5,840 )
Payments for patent applications and other costs     (317 )     (194 )
Proceeds from disposal of property, plant and equipment     50        
Net cash (used in) provided by investing activities     (4,451 )     4,391  
                 
Financing activities                
Change in restricted cash     (5,000 )      
Borrowings on long-term debt     5,000        
Principal payments on long-term debt     (2,837 )     (3,568 )
Proceeds from sale of common stock     341       383  
Tax benefit of stock based compensation           (147 )
Net cash used in financing activities     (2,496 )     (3,332 )
                 
Effect of exchange rate changes on cash flows     465       462  
                 
Decrease in cash and cash equivalents     (6,589 )     (2,241 )
                 
Cash and cash equivalents at beginning of period     19,984       25,747  
                 
Cash and cash equivalents at end of period   $ 13,395     $ 23,506  

 

See notes to unaudited condensed consolidated financial statements.

 

6
 

 

(All amounts in thousands, except per share amounts, unless otherwise noted)

 

Note 1 — Summary of Operations and Significant Accounting Policies

Nature of Business and Operations

 

Albany Molecular Research, Inc. (the “Company”) provides scientific services, technologies and products focused on improving the quality of life. With locations in the U.S., Europe, and Asia, the Company provides customers with a range of services and cost models. The Company’s core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing. The Company also owns a portfolio of proprietary technologies which have resulted from its internal programs, including drug discovery and niche generic products and manufacturing process efficiencies, some of which are licensed to third parties, and some of which benefit the Company’s operations.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In accordance with Rule 10-01, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by U.S. generally accepted accounting principles. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair statement of the results for the interim period have been included. Operating results for the three and six months ended June 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2011.

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated during consolidation. Assets and liabilities of non-U.S. operations are translated at period-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the period. Unrealized gains or losses resulting from translating non-U.S. currency financial statements are recorded in accumulated other comprehensive loss, net in the accompanying unaudited condensed consolidated balance sheets.

 

Use of Management Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates included in the accompanying consolidated financial statements include assumptions regarding the collectibility of receivables, the valuation of inventory, the fair value of intangible assets and long-lived assets, and the amount and realizabilty of deferred tax assets. Other significant estimates include assumptions utilized in determining actuarial obligations in conjunction with the Company’s pension and postretirement health plans, the estimation of restructuring charges, assumptions utilized in determining stock-based compensation, and assumptions associated with legal contingencies. Actual results can vary from these estimates.

 

Contract Revenue Recognition

 

The Company’s contract revenue consists primarily of fees earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company also seeks to include provisions in certain contracts that contain a combination of up-front licensing fees, milestone and royalty payments should the Company’s proprietary technology and expertise lead to the discovery of new products that become commercial. Reimbursed expenses consist of chemicals and other project specific costs. Generally, the Company’s contracts may be terminated by the customer upon 30 days’ to one year’s prior notice, depending on the terms and/or size of the contract. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the FASB’s Accounting Standards Codification (“ASC”) 605-25, “Revenue Arrangements with Multiple Deliverables,” and Staff Accounting Bulletin (“SAB”) 104, “Revenue Recognition”. Allocation of revenue to individual elements that qualify for separate accounting is based on the fair value of the respective elements.

 

7
 

 

The Company generates contract revenue on the following basis:

 

Full-time Equivalent (“FTE”).  An FTE agreement establishes the number of Company employees contracted for a project or a series of projects, the duration of the contract period, the price per FTE, plus an allowance for chemicals and other project specific costs, which may or may not be incorporated in the FTE rate. FTE contracts can run in one month increments, but typically have terms of six months or longer. FTE contracts typically provide for annual adjustments in billing rates for the scientists assigned to the contract.

 

These contracts involve the Company’s scientists providing services on a “best efforts” basis on a project that may involve a research component with a timeframe or outcome that has some level of unpredictability. There are no fixed deliverables that must be met for payment as part of these services. As such, the Company recognizes revenue under FTE contracts on a monthly basis as services are performed according to the terms of the contract.

 

Time and Materials .   Under a time and materials contract the Company charges customers an hourly rate plus reimbursement for chemicals and other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred.

 

Fixed-Fee . Under a fixed-fee contract the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. In certain instances, the Company’s customers request that the Company retain materials produced upon completion of the project due to the fact that the customer does not have a qualified facility to store those materials or for other reasons. In these instances, the revenue recognition process is considered complete when project documents (batch records, Certificates of Analysis, etc.) have been delivered to the customer and collection is reasonably assured.

 

Up-Front License Fees, Milestone, and Royalty Revenue . The Company recognizes revenue from up-front non-refundable licensing fees on a straight-line basis over the period of the underlying project. The Company will recognize revenue arising from a substantive milestone payment upon the successful achievement of the event, and the resolution of any uncertainties or contingencies regarding potential collection of the related payment, or, if appropriate, over the remaining term of the agreement.

 

Recurring Royalties Revenue Recognition

 

Recurring royalties consist of royalties under a license agreement with Sanofi based on the worldwide sales of fexofenadine HCl, marketed as Allegra in the Americas and Telfast elsewhere, as well as on sales of Sanofi’s authorized generics. The Company records royalty revenue in the period in which the sales of Allegra/Telfast occur, because it can reasonably estimate such royalties. Royalty payments from Sanofi are due within 45 days after each calendar quarter and are determined based on sales of Allegra/Telfast and Teva Pharmaceuticals’ sales of generic D-12 in that quarter.

 

Long-Lived Assets

 

The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable. Factors the Company considers important that could trigger an impairment review include, among others, the following:

 

· a significant change in the extent or manner in which a long-lived asset is being used;

 

· a significant change in the business climate that could affect the value of a long-lived asset; and

 

· a significant decrease in the market value of assets.

 

If the Company determines that the carrying value of long-lived assets may not be recoverable, based upon the existence of one or more of the above indicators of impairment, the Company compares the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is recorded to the extent that the carrying amount of the asset group exceeds its fair value and will reduce only the carrying amount of the long-lived assets.

 

8
 

 

Note 2 — Earnings Per Share

 

Both basic and diluted weighted average shares outstanding were 30,266 and 30,202 for the three and six months ended June 30, 2012 and 29,941 and 29,888 for the three and six months ended June 30, 2011.

 

The Company has excluded all outstanding stock options and non-vested restricted shares from the calculation of diluted earnings per share for the six months ended June 30, 2012 and the three and six months ended June 30, 2011 because the net loss causes these outstanding stock options and non-vested restricted shares to be anti-dilutive. The weighted average number of anti-dilutive options and restricted shares outstanding (before the effects of the treasury stock method) was 2,823 and 1,601 for the three months ended June 30, 2012 and 2011, respectively and 2,906 and 1,677 for the six months ended June 30, 2012 and 2011, respectively.

 

Note 3 — Inventory

 

Inventory consisted of the following at June 30, 2012 and December 31, 2011:

 

    June 30,
2012
    December 31,
2011
 
Raw materials   $ 9,435     $ 6,030  
Work in process     5,220       3,050  
Finished goods     21,224       16,924  
Total.   $ 35,879     $ 26,004  

  

Note 4 –Debt and restricted cash

Debt

In April 2012, the Company entered into a $20,000 credit facility consisting of a 4-year, $5,000 term loan and a $15,000 revolving line of credit. The Company used a portion of the initial proceeds to repay all amounts due under its prior credit agreement. As of June 30, 2012, the Company had $9,200 of outstanding letters of credit secured by the new line of credit.

 

Borrowings under this new April 2012 agreement will bear interest at a fluctuating rate equal to (i) in the case of the term loan, the sum of (a) an interest rate equal to daily three month LIBOR, plus (b) 3.25%; and (ii) in the case of advances under the revolving line of credit, the sum of (a) an interest rate equal to daily three month LIBOR, plus (b) 2.75%. As of June 30, 2012, the interest rate on the outstanding term loan was 3.75%.

 

The credit facility contains financial covenants, including certain net cash flow requirements for 2012, a minimum fixed charge coverage ratio commencing in 2013 and extending for the remaining term of the agreement, maximum quarterly year-to-date capital expenditures, minimum monthly domestic unrestricted cash and maximum average monthly cash reserves held at international locations. As of June 30, 2012, the Company was in compliance with its current financial covenants.

 

The Company maintains variable interest rate industrial development authority (“IDA”) bonds due in increasing annual installments through 2021. Interest payments are due monthly with a current interest rate of 0.28% at June 30, 2012. The amount outstanding as of June 30, 2012 was $2,990.

 

The following table summarizes long-term debt:

 

    June 30,
2012
    December 31,
2011
 
Term loan   $ 5,000     $ 2,550  
Industrial development authority bonds     2,990       3,275  
Miscellaneous loan     15       17  
      8,005       5,842  
Less current portion     (418 )     (2,839 )
Total long-term debt   $ 7,587     $ 3,003  

 

9
 

 

The aggregate maturities of long-term debt at June 30, 2012 are as follows:

 

2012 (remainder)   $ 2  
2013     775  
2014     1,024  
2015     1,029  
2016     1,034  
Thereafter     4,141  
Total   $ 8,005  

 

Restricted cash

 

Upon entering into a new credit agreement in April 2012, the Company was required to maintain a $5,000 restricted cash balance to partially collateralize the revolving line of credit.

 

Note 5 — Restructuring and Impairment

 

In March 2012, the Company approved a restructuring plan that ceased all operations at its Budapest, Hungary facility effective March 30, 2012. The goal of the restructuring plan is to advance the Company’s continued strategy of increasing global competitiveness and remaining diligent in managing costs by improving efficiency and customer service and by realigning resources to meet shifting customer demand and market preferences. In connection with this closure, the Company recorded a restructuring charge in its DDS operating segment of $672 in the first quarter of 2012 and $1,255 in the second quarter of 2012.  These amounts included $1,337 for termination benefits and $590 for preparing the facility for closure and other administrative costs.  Restructuring charges for the six months ended June 30, 2012 did not include costs associated with terminating the Budapest facility lease.  The Company is currently preparing the Budapest facility for closure and is negotiating the termination of the lease agreement.  The Company currently anticipates completing these lease termination activities in the second half of 2012, at which point additional restructuring charges will be recognized.  The Company currently estimates that lease termination charges associated with its Budapest facility will range between $1,000 and $2,000.

 

In conjunction with the decision to cease operations at the Company’s Budapest, Hungary facility as discussed above, the Company also recorded property and equipment impairment charges of $3,967 in our DDS segment in the first quarter of 2012. These charges are included under the caption “Property and equipment impairment charges” on the consolidated statement of operations for the six months ended June 30, 2012.

 

In March 2011, the Company reduced its workforce to right-size its U.S. operations, primarily focused on discovery chemistry services due to the shift in demand for these types of services to the Company’s lower cost operations in Asia. In connection with this reduction, the Company recorded a restructuring charge of $951 for termination benefits. These restructuring activities were recorded within the Company’s DDS operating segment.

 

In December 2011, the Company initiated a restructuring plan at one of its U.S. locations which included actions to further reduce the Company's workforce, right size capacity, and reduce operating costs. These actions were implemented to better align the business to current and expected market conditions and are expected to improve the Company's overall cost competitiveness and increase cash flow generation. The workforce reduction primarily affected certain positions associated with the Company’s elimination of internal R&D activities.  As a result of the workforce reduction, the Company will be terminating the lease of one of its U.S. facilities which will result in a reduction in annual operating expenses related to this facility.  As a result of this restructuring, the Company recorded restructuring charges in the DDS operating segment of $200 in the first half of 2012 and $320 in the fourth quarter of 2011.

 

The following table displays the restructuring activity and liability balances for the six months ended June 30, 2012:

 

    Balance at
December 31, 2011
    Charges/
(reversals)
    Paid Amounts     Foreign
Currency
Translation
Adjustments
    Balance at
June 30, 2012
 
Termination benefits and personnel realignment   $ 456       950       (758 )     (2 )     646  
Lease termination and relocation charges     1,128       924       (1,280 )     -       772  
Other     354       253       (521 )     4       90  
Total   $ 1,938       2,127       (2,559 )     2     $ 1,508  

 

10
 

 

Termination benefits and personnel realignment costs relate to severance packages, outplacement services, and career counseling for employees affected by the restructuring. Lease termination charges relate to costs associated with exiting a facility, net of estimated sublease income.

 

Restructuring charges are included under the caption “Restructuring charges” in the consolidated statement of operations for the three and six months ended June 30, 2012 and 2011 and the restructuring liabilities are included in “Accounts payable and accrued expenses” and “other long-term liabilities” on the consolidated balance sheet at June 30, 2012 and December 31, 2011.

 

Anticipated cash outflow related to the restructurings for the remainder of 2012 is approximately $1,289, plus any cash consideration of the Hungary lease term settlement.

 

Note 6 —Intangible Assets

 

The components of intangible assets are as follows:

 

    Cost     Accumulated
Amortization
    Net     Amortization
Period
 
June 30, 2012                                
Patents and Licensing Rights   $ 4,099     $ (1,520 )   $ 2,579       2-16 years  
Customer Relationships     815       (332 )     483       5 years  
    $ 4,914     $ (1,852 )   $ 3,062          
                                 
December 31, 2011                                
Patents and Licensing Rights   $ 3,756     $ (1,343 )   $ 2,413       2-16 years  
Customer Relationships     815       (252 )     563       5 years  
Total   $ 4,571     $ (1,595 )   $ 2,976          

  

Amortization expense related to intangible assets was $108 and $135 for the three months ended June 30, 2012 and 2011, respectively, and $225 and $254 for the six months ended June 30, 2012 and 2011, respectively.

 

The following chart represents estimated future annual amortization expense related to intangible assets:

 

Year ending December 31,      
2012 (remaining)   $ 297  
2013     405  
2014     399  
2015     242  
2016     211  
Thereafter     1,508  
Total   $ 3,062  

 

Note 7 — Share-Based Compensation

 

During the three and six months ended June 30, 2012, the Company recognized total share based compensation cost of $527 and $1,066, respectively, as compared to total share based compensation cost for the three and six months ended June 30, 2011 of $386 and $745, respectively.

 

The Company grants share-based compensation, including restricted shares, under its 2008 Stock Option and Incentive Plan, as well as its 1998 Employee Stock Purchase Plan.

 

11
 

 

Restricted Stock

 

A summary of unvested restricted stock activity as of June 30, 2012 and changes during the six months then ended is presented below:

 

    Number of
Shares
    Weighted
Average Grant Date
Fair Value Per Share
 
Outstanding, January 1, 2012     561     $ 7.14  
Granted     85     $ 2.93  
Vested     (100 )   $ 8.96  
Forfeited     (15 )   $ 6.37  
Outstanding, June 30, 2012     531     $ 6.15  

 

The weighted average fair value of restricted shares per share granted during the six months ended June 30, 2012 and 2011 was $2.93 and $5.22, respectively. As of June 30, 2012, there was $2,318 of total unrecognized compensation cost related to unvested restricted shares. That cost is expected to be recognized over a weighted-average period of 2.4 years.

 

Stock Options

 

The fair value of each stock option award is estimated at the date of grant using the Black-Scholes valuation model based on the following assumptions:

 

    For the Six Months Ended  
    June 30, 2012     June 30, 2011  
Expected life in years     5       5  
Risk free interest rate     0.88 %     1.92 %
Volatility     57 %     56 %
Dividend yield            

 

A summary of stock option activity under the Company’s Stock Option and Incentive Plans as of June 30, 2012 and changes during the six month period then ended is presented below:

 

    Number of
Shares
    Weighted Average
Exercise
Price Per Share
    Weighted Average
Remaining
Contractual Term
(Years)
    Aggregate
Intrinsic
Value
 
Outstanding, January 1, 2012     2,762     $ 7.58                  
Granted     330       2.86                  
Exercised                            
Forfeited     (113 )     10.70                  
Expired     (131 )     25.13                  
Outstanding, June 30, 2012     2,848     $ 6.11       7.4     $ 306  
Options exercisable, June 30, 2012     994     $ 11.63       3.9     $  

 

The weighted average fair value of stock options granted for the six months ended June 30, 2012 and 2011 was $1.40 and $2.54, respectively. As of June 30, 2012, there was $2,379 of total unrecognized compensation cost related to non-vested stock options. That cost is expected to be recognized over a weighted-average period of 2.4 years.

 

Employee Stock Purchase Plan

 

During the six months ended June 30, 2012 and 2011, 93 and 67 shares, respectively, were issued under the Company’s 1998 Employee Stock Purchase Plan.

 

During the six months ended June 30, 2012 and 2011, cash received from stock option exercises and employee stock purchases was $341 and $383, respectively. The actual tax benefit realized for the tax deductions from share based compensation was $0 and $147 for the six months ended June 30, 2012 and 2011.

 

Note 8 — Operating Segment Data

 

The Company has organized its sales, marketing and production activities into the DDS and LSM segments based on the criteria set forth in ASC 280, “Disclosures about Segments of an Enterprise and Related Information”. The Company’s management relies on an internal management accounting system to report results of the segments. The system includes revenue and cost information by segment. The Company’s management makes financial decisions and allocates resources based on the information it receives from this internal system.

 

DDS includes activities such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. LSM includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. Corporate activities include business development and administrative functions, as well as research and development costs that have not been allocated to the operating segments.

 

The following table contains earnings data by operating segment, reconciled to totals included in the unaudited condensed consolidated financial statements:

 

12
 

 

    Contract
Revenue
    Milestone &
Recurring
Royalty
Revenue
    Income
(Loss) 
from Operations
    Depreciation
and
Amortization
 
For the three months ended June 30, 2012                                
DDS   $ 16,657     $ 7,529     $ 5,528     $ 2,447  
LSM     25,733       90       5,807       1,918  
Corporate                 (9,841 )      
Total   $ 42,390     $ 7,619     $ 1,494     $ 4,365  
                                 
For the three months ended June 30, 2011                                
DDS   $ 18,029     $ 10,380     $ 7,961     $ 2,576  
LSM     25,468             2,029       1,854  
Corporate                 (9,786 )      
Total   $ 43,497     $ 10,380     $ 204     $ 4,430  

 

    Contract
Revenue
    Milestone &
Recurring
Royalty
Revenue
    Income
(Loss) 
from Operations
    Depreciation
and
Amortization
 
For the six months ended June 30, 2012                                
DDS   $ 36,117     $ 18,514     $ 11,009     $ 5,041  
LSM     48,983       90       8,224       3,859  
Corporate                 (19,687 )      
Total   $ 85,100     $ 18,604     $ (454 )   $ 8,900  
                                 
For the six months ended June 30, 2011                                
DDS   $ 39,144     $ 24,396     $ 18,660     $ 5,040  
LSM     47,284             1,651       3,787  
Corporate                 (21,198 )      
Total   $ 86,428     $ 24,396     $ (887 )   $ 8,827  

 

The following table summarizes other information by segment as of and for the six month period ended June 30, 2012:

 

    DDS     LSM     Total  
Total assets   $ 139,605     $ 127,774     $ 267,379  
Investments in unconsolidated affiliates     956             956  
Capital expenditures     1,523       2,874       4,397  

 

The following table summarizes other information by segment as of and for the year ended December 31, 2011:

 

    DDS     LSM     Total  
Total assets   $ 146,017     $ 117,050     $ 263,067  
Investments in unconsolidated affiliates     956             956  
Capital expenditures     6,578       4,198       10,776  

 

Note 9 — Financial Information by Customer Concentration and Geographic Area

 

Total contract revenue from DDS’s three largest customers represented approximately 9%, 8% and 6% of DDS’s total contract revenue for the three months ended June 30, 2012, and 11%, 9% and 8% of DDS’s total contract revenue for the three months ended June 30, 2011. Total contract revenue from DDS’s three largest customers represented approximately 10%, 7% and 5% of DDS’s total contract revenue for the six months ended June 30, 2012 and 11%, 8% and 7% for the six months ended June 30, 2011. Total contract revenue from LSM’s largest customer, GE Healthcare (“GE”), represented 23% and 20% of LSM’s total contract revenue for the three months ended June 30, 2012 and 2011, respectively. Total contract revenue from GE represented 25% and 28% of LSM’s total contract revenue for the six months ended June 30, 2012 and 2011, respectively. GE accounted for approximately 15% of the Company’s total contract revenue for both the six months ended June 30, 2012 and 2011.

 

13
 

 

The Company’s total contract revenue for the three and six months ended June 30, 2012 and 2011 was recognized from customers in the following geographic regions:

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2012     2011     2012     2011  
                         
United States     57 %     55 %     59 %     59 %
Europe     20       25       20       18  
Asia     21       17       17       21  
Other     2       3       4       2  
                                 
Total     100 %     100 %     100 %     100 %

 

Long-lived assets by geographic region are as follows:

 

    June 30, 
2012
    December  31,
2011
 
United States   $ 119,723     $ 123,245  
Asia     19,008       19,015  
Europe     6,518       10,512  
Total long-lived assets   $ 145,249     $ 152,772  

 

Note 10 — Legal Proceedings

 

The Company, from time to time, may be involved in various claims and legal proceedings arising in the ordinary course of business. Except as noted below, the Company is not currently a party to any such claims or proceedings which, if decided adversely to the Company, would either individually or in the aggregate have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

 

Allegra

 

The Company, along with Aventis Pharmaceuticals Inc., the U.S. pharmaceutical business of Sanofi, has been involved in legal proceedings with several companies seeking to market or which are currently marketing generic versions of Allegra and Allegra-D. In accordance with the Company’s agreements with Sanofi, Sanofi bears the external legal fees and expenses for these legal proceedings, but in general, the Company must consent to any settlement or other arrangement with any third party. Under those same agreements, the Company will receive royalties from Sanofi on U.S. Patent No. 5,578,610 until its expiration in 2013 and royalties on U.S. Patent No. 5,750,703 until its expiration in 2015, unless those patents are earlier determined to be invalid. Similarly, the Company is entitled to receive royalties from Sanofi on certain foreign patents through 2015, unless those patents are earlier determined to be invalid. The Company is also entitled to receive certain royalties from Sanofi in certain foreign countries through mid 2015, unless certain patents are earlier determined to be invalid.

 

United States Litigations

 

Beginning in 2001, Barr Laboratories, Inc., Impax Laboratories, Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Dr. Reddy’s Laboratories, Ltd./Dr. Reddy’s Laboratories, Inc., Ranbaxy Laboratories Ltd./Ranbaxy Pharmaceuticals Inc., Sandoz Inc., Sun Pharma Global, Inc., Wockhardt and Actavis Mid Atlantic LLC, and AurolifePharma LLC and AurobindoPharma Ltd. filed Abbreviated New Drug Applications (“ANDAs”) with the Food and Drug Administration (“FDA”) to produce and market generic versions of Allegra products.

 

In response to the filings described above, beginning in 2001, Aventis Pharmaceuticals (now Sanofi) filed patent infringement lawsuits against each of the above referenced companies.  Each of the lawsuits was filed in the U.S. District Court in New Jersey and alleges infringement of one or more patents owned by Aventis Pharmaceuticals. In addition, beginning on November 14, 2006, Sanofi filed two patent infringement suits against Teva Pharmaceuticals USA, Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc. in the Eastern District of Texas based on patents owned by Aventis.  Those lawsuits were transferred to the U.S. District Court in New Jersey.

 

Further, beginning on March 5, 2004, the Company, along with Aventis Pharmaceuticals, filed suit in the U.S. District Court in New Jersey against a number of defendants asserting infringement of U.S. Patent Nos. 5,581,011 and 5,750,703, which are exclusively licensed to Aventis Pharmaceuticals and relate to Allegra and Allegra-D products.  On September 9, 2009, the Company filed patent infringement lawsuits in the U.S. District Court in New Jersey against Dr. Reddy’s Laboratories, Ltd, Dr. Reddy’s Laboratories, Inc., and Sandoz, Inc. asserting infringement of U.S. Patent No. 7,390,906. That patent is licensed to Sanofi U.S. LLC and Sanofi U.S. LLC joined that lawsuit as a co-plaintiff with the Company.

 

14
 

 

On November 18, 2008, the Company, Aventis Pharmaceuticals, Sanofi, Teva Pharmaceuticals, and Barr Laboratories reached a settlement regarding the above-described patent infringement litigations relating to Teva Pharmaceuticals and Barr Laboratories (the “Teva Settlement”).  As part of the Teva Settlement, the Company entered into an amendment to its licensing agreement with Sanofi to allow Sanofi to sublicense patents related to ALLEGRA ® and ALLEGRA ® D-12 to Teva Pharmaceuticals and Barr Laboratories in the United States.  Subsequently, Teva Pharmaceuticals acquired Barr Laboratories.  The Company received an upfront sublicense fee from Sanofi of $10 million, and Sanofi will pay royalties to the Company on the sale of products in the United States containing fexofenadine hydrochloride (the generic name for the active ingredient in ALLEGRA ® ) and products containing fexofenadine hydrochloride and pseudoephedrine hydrochloride (generic ALLEGRA ® D-12) by Teva Pharmaceuticals through 2015, along with additional consideration.   The Company received quarterly royalties through July 2010 for the branded Allegra D-12 equal to the royalties paid for the quarter ended June 30, 2009.  Thereafter, the royalty rate has reverted to the rate in effect prior to the signing of the sub-license amendment and the Company will also receive a royalty on Teva’s sales of the generic Allegra D-12.  The Company and Aventis Pharmaceuticals have also dismissed their claims against Ranbaxy Laboratories Ltd./Ranbaxy Pharmaceuticals Inc. and Sandoz, Inc. without prejudice. 

 

On March 19, 2010, the Company and Sanofi filed a motion for a preliminary injunction in the U.S. District Court in New Jersey seeking to enjoin Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. from commercial distribution of a Allegra D-24 product based in that product infringing U.S. Patent No. 7,390,906.   On June 14, 2010, the Company and Sanofi were granted a preliminary injunction restraining Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. from commercial distribution of a D-24 product.  On January 13, 2011, the same court issued a decision interpreting the scope of the claims of U.S. Patent No. 7,390,906.  Based on the court’s January 13, 2011 interpretation of the scope of a claim term in U.S. Patent No. 7,390,906, the Company does not presently have evidence sufficient to obtain a favorable outcome on its infringement claim against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.   As a result, the Company, along with Sanofi, Dr. Reddy’s Laboratories, Ltd., and Dr. Reddy’s Laboratories, Inc., agreed to the court’s entry of an order on January 28, 2011, finding that there was no infringement of U.S. Patent No. 7,390,906 based on the Court’s January 13, 2011 claim interpretation. The court’s January 28, 2011 order also dissolved the preliminary injunction that was entered on June 14, 2010.  The Company and Sanofi U.S. LLC have proceeded directly to the U.S. Court of Appeals for the Federal Circuit to appeal the January 13, 2011 decision.

 

The January 13, 2011, decision also included an interpretation of the scope of the claims of U.S. Patent No. 5,750,703, and based on that interpretation, the Company does not presently have evidence sufficient to obtain a favorable outcome on its infringement claim against Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc., Amino Chemicals Ltd., Dipharma S.P.A., and Dipharma Francis Sr.l As a result, the Company, along with Sanofi, Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc. Amino Chemicals Ltd., Dipharma S.P.A., and Dipharma Francis Sr.l agreed to the court’s entry of an order on March 28, 2011, finding that there was no infringement of U.S. Patent No. 5,750,703 based on the Court’s January 13, 2011 claim interpretation. The Company and Sanofi U.S. LLC have proceeded directly to the U.S. Court of Appeals for the Federal Circuit to appeal the January 13, 2011 decision.

 

In June 2011, the Company, Sanofi and Impax Laboratories, Inc. reached a settlement agreement for the above patent infringement litigation relating to Impax (“Impax Settlement”). In conjunction with the Impax Settlement, the Company and Sanofi agreed to amend their license agreement to allow Sanofi to sublicense patents related to ALLEGRA ® and ALLEGRA ® D-12 to Impax Laboratories, Inc. in the United States.  Additionally, the Company, Sanofi, Mylan Pharmaceuticals, Inc., and Alphapharm reached a settlement agreement of the above patent infringement litigation relating to Mylan and the below noted litigation in Australia against Mylan affiliate Alphapharm (“Mylan Settlement”). In conjunction with the Mylan Settlement, the Company and Sanofi agreed to amend their license agreement to allow Sanofi to sublicense patents related to ALLEGRA ® and ALLEGRA ® D-12 to Mylan Pharmaceuticals, Inc. in the United States.  

 

International Litigations

 

In 2007, the Company filed patent infringement lawsuits in Australia against Alphapharm Pty Ltd., Arrow Pharmaceuticals Pty Ltd, Chemists’ Own Pty Ltd, and Sigma Pharmaceuticals Limited based on Australian Patent No. 699,799.  These matters were heard in a consolidated trial in November and December 2010. On February 17, 2011, the Court ruled that the defendants are not liable for infringement because the asserted claims of the Australian Patent No. 699,799 are invalid for lack of novelty and false suggestion. An appeal has been filed with regard to the ruling in the case against Arrow. The action against Alphapharm was settled as part of the Mylan Settlement, with Alphapharm receiving a sublicense to sell its products in Australia and New Zealand. The Company has also settled its suit against Arrow Pharmaceuticals Pty Ltd, Chemists’ Own Pty Ltd, and Sigma Pharmaceuticals Limited, with those parties receiving a sublicense to sell their products in Australia. Notwithstanding the court’s ruling of non-infringement, the Company continues to receive royalties on sales of the Allegra products in Australia.

 

15
 

 

 

   

At Risk Launches

 

Under applicable federal law, marketing of an FDA-approved generic version of Allegra may not commence until the earlier of a decision favorable to the generic challenger in the patent litigation or 30 months after the date the patent infringement lawsuit was filed. In general, the first generic filer is entitled to a 180-day marketing exclusivity period upon FDA approval.  The launch of a generic product is considered an “at-risk” launch if the launch occurs while there is still on-going litigation.  Of the remaining defendants in the pending United States litigation, Dr. Reddy’s Laboratories has engaged in an at-risk launch of a generic fexofenadine single-entity product.

 

Note 11 – Fair Value

 

The Company uses a framework for measuring fair value in generally accepted accounting principles and making disclosures about fair value measurements.  A three-tiered fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value.  

 

These tiers include:  

Level 1 – defined as quoted prices in active markets for identical instruments;

Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The Company did not use any level 3 inputs in measuring the fair value of any of its financial instruments in the six months ended June 30, 2012.

 

The Company determines its fair value of financial instruments using the following methods and assumptions:

 

Cash and cash equivalents, restricted cash, receivables, and accounts payable:  The carrying amounts reported in the consolidated balance sheets approximate their fair value because of the short maturities of these instruments.

 

Debt:  The carrying value of long-term debt was approximately equal to fair value at June 30, 2012 and December 31, 2011 due to the resetting dates of the variable interest rates.

 

16
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

The following discussion of our results of operations and financial condition should be read in conjunction with the accompanying Condensed Consolidated Financial Statements and the Notes thereto included within this report. This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by forward-looking words such as “may,” “could,” “should,” “would,” “will,” “intend,” “expect,” “anticipate,” “believe,” and “continue” or similar words and include, but are not limited to, statements concerning pension and postretirement benefit costs, the Company’s relationship with its largest customers, the Company’s collaboration with Bristol-Myers Squibb (“BMS”), future acquisitions, earnings, contract revenues, costs and margins, royalty revenues, patent protection and the ongoing Allegra® patent infringement litigation, Allegra® royalty revenue, government regulation, retention and recruitment of employees, customer spending and business trends, foreign operations, including increasing options and solutions for customers, business growth and the expansion of the Company’s global market, clinical supply manufacturing, management’s strategic plans, drug discovery, product commercialization, license arrangements, research and development projects and expenses, revenue and expense expectations for future periods, long-lived asset impairment, competition and tax rates. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause such differences include, but are not limited to, those discussed in Part I, Item 1A, “Risk Factors”, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission on March 15, 2012, as updated by Part II Item 1A, “Risk Factors,” in subsequent Forms 10-Q. All forward-looking statements are made as of the date of this report, and we do not undertake to update any such forward-looking statements in the future, except as required by law. References to “AMRI”, the “Company,” “we,” “us,” and “our,” refer to Albany Molecular Research, Inc. and its subsidiaries, taken as a whole.

 

Strategy and Overview

 

We are a global contract research and manufacturing organization that provides customers fully integrated drug discovery, development, and manufacturing services. We supply a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of active pharmaceutical ingredients (“API”) and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, we maintain geographic proximity and flexible cost models. We have also historically leveraged our drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. We have successfully partnered certain programs and are actively seeking to out-license our remaining programs to strategic partners for further development.

 

We continue to integrate our research and manufacturing facilities worldwide, increasing our access to key global markets and enabling us to provide our customers with a flexible combination of high quality services and competitive cost structures to meet their individual outsourcing needs.  Our service offerings range from early stage discovery through manufacturing and formulation across U.S., Europe and Asia. We believe that the ability to partner with a single provider is of significant benefit to our customers as we are able to provide them with a more efficient transition of experimental compounds through the research and development process, ultimately reducing the time and cost involved in bringing these compounds from concept to market. Compounds discovered and/or developed in our contract research facilities can then be more easily transitioned to production at our large-scale manufacturing facilities for use in clinical trials and, ultimately, commercial sales if the product meets regulatory approval.  

 

Additionally, we offer our customers a fully integrated manufacturing process for sterile injectable drugs. This includes the development and manufacture of the API, the design of the criteria to formulate the API into an injectable drug product, and the manufacture of the final drug product. We continue to make investments to build and recover our formulation business, as we believe this type of business has significant potential in the drug product world driven by the growth in biologically based compounds which are formulated/manufactured on an aseptic basis.

 

In addition to providing our customers our hybrid services model for outsourcing, we now offer the option of insourcing. With our world class expertise in managing high performing groups of scientists, this option allows us to embed our scientists into the customer’s facility allowing the customer to cost effectively leverage their unused laboratory space.

 

17
 

 

As our customers continue to seek innovative new strategies for R&D efficiency and productivity, we are aggressively realigning our business and resources to address their needs. To that end, we have launched AMRI SMARTSOURCING™, a cross functional approach that maximizes the strengths of both insourcing and outsourcing, by leveraging AMRI’s people, know-how, facilities, expertise and global project management to provide exactly what is needed across the discovery or development process. We have also streamlined our sales and marketing organization to optimize cross-selling opportunities and, enhanced our commitment to quality with the appointment of key personnel at our Burlington aseptic services facility, both underscoring our dedication to client service. Our improved organizational structure, combined with more focused marketing efforts should enable us to continue to drive long term growth and profitability.”

 

In 2011, we made a decision to cease activities related to our internal proprietary compound discovery R&D programs. Although we halted our proprietary R&D activities, we continue to believe there are additional opportunities to partner our proprietary compounds or programs to create value, as we have seen a renewed commitment by pharmaceutical companies for innovation both internally and through licensing. Our goal is to partner these compounds or programs in return for a combination of up-front license fees, milestone payments and recurring royalty payments if any compound based on our intellectual property is successfully developed into new drugs and reach the market.

 

In March 2012, we approved a restructuring plan that ceased all operations at our Budapest, Hungary facility effective March 30, 2012. The goal of the restructuring plan is to advance our continued strategy of increasing global competitiveness and remaining diligent in managing costs by improving efficiency and customer service and by realigning resources to meet shifting customer demand and market preferences.

 

Our total revenue for the quarter ended June 30, 2012 was $50.0 million, as compared to $53.9 million for the quarter ended June 30, 2011.

 

Contract services revenue for the second quarter of 2012 was $42.4 million, compared to $43.5 million for the same quarter in 2011. Recurring royalty revenues, which are based on the worldwide sales of fexofenadine HCl, marketed as Allegra in the Americas and Telfast elsewhere, as well as on sales of Sanofi’s over-the-counter product, authorized generics and estimates of sales of Teva’s authorized generics, increased 2% in the second quarter of 2012 from the same period in 2011. Consolidated gross margin was 14.5% for the quarter ended June 30, 2012 as compared to 5.3% for the quarter ended June 30, 2011.

 

During the six months ended June 30, 2012, cash used in operations was $0.1 million compared to cash used in operations of $3.8 million for the same period of 2011. This change from the six months ended June 30, 2011 resulted primarily from a payment of $4.8 million in the first quarter of 2011 associated with the Company’s arbitration settlement with a supplier. During the six months ended June 30, 2012, we spent $4.4 million in capital expenditures, primarily related to domestic modernization of our lab and production equipment. As of June 30, 2012, we had $13.4 million in unrestricted cash and cash equivalents and $8.0 million in bank and other related debt.

 

Results of Operations – Three and Six Months ended June 30, 2012 Compared to Three and Six Months Ended June 30, 2011

 

Revenues

 

Total contract revenue

 

Contract revenue consists primarily of fees earned under contracts with our third party customers. Our contract revenues for each of our Discovery/Development/Small Scale Manufacturing (“ DDS”) and Large-Scale Manufacturing (“LSM”) segments were as follows:

 

    Three Months Ended June 30,     Six Months Ended June 30,  
(in thousands)   2012     2011     2012     2011  
                         
DDS   $ 16,657     $ 18,029     $ 36,117     $ 39,144  
LSM     25,733       25,468       48,983       47,284  
Total   $ 42,390     $ 43,497     $ 85,100     $ 86,428  

 

The decrease in DDS contract revenue for the three and six months ended June 30, 2012 from the same periods in 2011 is primarily due to lower contract revenue for our development and small-scale manufacturing services of $1.0 million and $1.7 million, respectively, as a result of lower demand for our U.S. chemistry development services. Additionally, contract revenue for our discovery services in the three and six months ended June 30, 2012 decreased $0.4 million and $1.3 million, respectively, from the same period in 2011 primarily caused by lower demand for our U.S. biology services, along with decreased revenues due to the closure of our Hungarian operations. These decreases were offset in part by higher demand for our U.S. chemistry discovery services.

 

18
 

 

We currently expect DDS contract revenue for full year 2012 to approximate amounts recognized in 2011.

 

LSM contract revenue remained flat for the three months ended June 30, 2012 and increased for the six months ended June 30, 2012 from the same periods in 2011. The increase for the six months ended June 30, 2012 was primarily due to an increase in clinical supply manufacturing services at our Rensselaer, NY facility of $1.1 million, as well as continued improvement in clinical manufacturing services revenue at our Burlington, MA facility. These increases were offset, in part, by a decrease in contract revenue from our intermediate manufacturing in our Aurangabad, India facility as compared to the same period in 2011.

 

We currently expect LSM contract revenue for full year 2012 to significantly increase from amounts recognized in 2011 driven by robust U.S. commercial API demand, an increase in our Phase III portfolio, and improved revenues from our Burlington, MA and UK facilities.

 

 

Recurring royalty revenue

 

We earn royalties under our licensing agreement with Sanofi for the active ingredient in Allegra. Royalties were as follows:

  

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 7,529     $ 7,380     $ 18,514     $ 21,396  

 

Recurring royalties are based on the worldwide sales of Allegra®/Telfast, as well as on sales of Sanofi over-the-counter (“OTC”) product and authorized generics. Recurring royalties increased slightly during the quarter ended June 30, 2012 from the same period in 2011.

 

Recurring royalties decreased for the six months ended June 30, 2012 from the same period in 2011 primarily due to a decrease in royalties recognized from the sales of prescription Allegra® in Japan in the first quarter of 2012 as a result of a less severe allergy season.

 

We currently expect full year 2012 recurring royalties to decrease from amounts recognized in 2011. We are anticipating recurring royalties to increase in the second half of 2012 from amounts recognized in the same period of 2011 as amounts in 2011 were impacted by prescription inventory reductions and marketing incentives associated with the OTC launch.

 

The recurring royalties we receive on the sales of Allegra®/Telfast have historically provided a material portion of our revenues, earnings and operating cash flows. We continue to develop our business in an effort to supplement the revenues, earnings and operating cash flows that have historically been provided by Allegra®/Telfast royalties.

 

Milestone revenue

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 90     $ 3,000     $ 90     $ 3,000  

 

Milestone revenue for the three and six months ended June 30, 2012 was recognized in conjunction with a development and supply agreement at the Company’s Rensselaer, NY manufacturing facility.

 

Milestone revenue of $3.0 million received during the three months ended June 30, 2011 was recognized in conjunction with the Company’s license and research agreement with BMS for initiating a Phase II clinical trial of an AMRI compound licensed exclusively to BMS.

 

19
 

 

Costs and Expenses

 

Cost of contract revenue

 

Cost of contract revenue consists primarily of compensation and associated fringe benefits for employees, as well as chemicals, depreciation and other indirect project related costs. Cost of contract revenue for our DDS and LSM segments were as follows:

 

Segment   Three Months Ended June 30,     Six Months Ended June 30,  
(in thousands)   2012     2011     2012     2011  
                         
DDS   $ 16,308     $ 17,927     $ 35,148     $ 37,662  
LSM     19,943       23,259       40,773       45,066  
Total   $ 36,251     $ 41,186     $ 75,921     $ 82,728  
                                 
DDS Gross Margin     2.1 %     0.6 %     2.7 %     3.8 %
LSM Gross Margin     22.5 %     8.7 %     16.8 %     4.7 %
Total Gross Margin     14.5 %     5.3 %     10.8 %     4.3 %

 

DDS contract revenue gross margin percentage increased for the three months ended June 30, 3012 compared to the same period in 2011 as a result of cost savings initiatives taken in our U.S chemistry operations in 2011, as well as the impact of the closure of our Hungarian operations in 2012.

 

DDS contract revenue gross margin percentage decreased for the six months ended June 30, 2012 compared to contract gross margin percentage for the same period in 2011 as a result of lower demand for our U.S. biology and development services in relation to our fixed costs, partially offset by cost savings initiatives taken in our U.S. chemistry operations and the closure of our Hungarian operations.

 

We currently expect DDS contract margins for 2012 to improve over amounts recognized in 2011 due to cost reduction actions implemented in the U.S. in 2011 along with the impact of the closure of our Hungarian operations as well as an increase in U.S. chemistry services revenue in the second half of 2012.

 

LSM’s contract revenue gross margin percentages improved for the three and six months ended June 30, 2012 compared to the same period in 2011 primarily due to an increase in sales of higher margin products for our U.S. manufacturing services, as well as an increase in capacity utilization at our large-scale manufacturing facilities worldwide as we progress toward fulfilling customer orders that we expect to complete in the second half of 2012.

 

We currently expect LSM contract margins for 2012 to significantly improve from amounts recognized in 2011 driven by improved capacity utilization, along with shift in revenues to higher margin commercial products.

 

Technology incentive award

 

We maintain a Technology Development Incentive Plan, the purpose of which is to stimulate and encourage novel innovative technology developments by our employees. This plan allows eligible participants to share in a percentage of the net revenue earned by us relating to patented technology with respect to which the eligible participant is named as an inventor or made a significant intellectual contribution. To date, the royalties from Allegra® are the main driver of the awards. Accordingly, as the creator of the technology, the award is currently payable primarily to Dr. Thomas D’Ambra, the Chief Executive Officer and President of the Company. The incentive awards were as follows:

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 753     $ 791     $ 1,852     $ 2,193  

 

Technology incentive award expense for the three months ended June 30, 2012 remained consistent with expense recognized for the same period in 2011. The decrease in technology incentive award expense for the six months ended June 30, 2012 as compared to the same period in 2011 is associated with the decrease in Allegra recurring royalty revenue as discussed above.

 

We expect technology incentive award expense to generally fluctuate directionally and proportionately with fluctuations in Allegra royalties in future periods.

 

20
 

 

Research and development

 

Research and development (“R&D”) expense consists of compensation and benefits for scientific personnel for work performed on proprietary technology R&D projects, costs of chemicals, materials, outsourced activities and other out of pocket costs and overhead costs.

 

During the fourth quarter of 2011, the Company’s Board of Directors made a decision to cease activities related to its internal discovery research and development programs, excluding its generic program. Although we ceased our proprietary R&D activities, we continue to believe there are additional opportunities to partner our proprietary compounds in return for a combination of up-front license fees, milestone payments and recurring royalty payments if these compounds are successfully developed into new drugs and reach the market. In addition, R&D activities continue at our large-scale manufacturing facility related to the potential manufacture of new products, the development of processes for the manufacture of generic products with commercial potential, and the development of alternative manufacturing processes.

 

Research and development expenses were as follows:

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 231     $ 1,910     $ 604     $ 4,514  

 

R&D expense for the three and six months ended June 30, 2012 decreased from the same periods in 2011 as a result of our strategic decision during the fourth quarter of 2011 to cease R&D operations related to our internal discovery research and development programs, excluding our generics program. R&D expenditures incurred in the first half of 2012 related primarily to developing new niche generic products and improving process efficiencies in our manufacturing plants.

 

We currently expect full year 2012 R&D expense to reduce to approximately $1.0 million, with costs primarily related to developing new niche generic products and improving process efficiencies in our manufacturing plants.

 

Selling, general and administrative

 

Selling, general and administrative (“SG&A”) expenses consist of compensation and related fringe benefits for selling, marketing, operational and administrative employees, professional service fees, marketing costs and costs related to facilities and information services.

 

SG&A expenses were as follows:

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 9,841     $ 9,786     $ 19,687     $ 21,198  

   

SG&A expenses remained flat for the three months ended June 30, 2012 when compared to the same period in 2011. The decrease in SG&A expenses for the six months ended June 30, 2012 from the comparable prior year period is primarily attributable to cost savings actions implemented in the U.S. in 2011. Additionally, in the first half of 2011 we incurred charges attributable to AMRI Burlington’s remediation efforts to remediate certain issues identified during an inspection by the FDA in 2010.

 

We currently expect SG&A expenses for 2012 to decrease due to the closure of our Hungarian operations, as well as other cost saving actions implemented in the U.S. in 2011.

 

Restructuring

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 1,439     $ -     $ 2,127     $ 951  

 

21
 

 

In March 2012, we approved a restructuring plan that ceased all operations at our Budapest, Hungary facility effective March 30, 2012. The goal of the restructuring plan is to advance our continued strategy of increasing global competitiveness and remaining diligent in managing costs by improving efficiency and customer service and by realigning resources to meet shifting customer demand and market preferences. In connection with this closure, the Company recorded a restructuring charge of $1.9 million in its DDS operating segment in the first half of 2012.  This amount included $1.3 million for termination benefits and $0.6 million for preparing the facility for closure and other administrative costs.  Restructuring charges for the six months ended June 30, 2012 did not include costs associated with terminating the Budapest facility lease.  The Company is currently preparing the Budapest facility for closure and is negotiating the termination of the lease agreement.  The Company currently anticipates completing these lease termination activities in the second half of 2012, at which point additional restructuring charges will be recognized.  The Company currently estimates that lease termination charges associated with its Budapest facility will range between $1.0 million and $2.0 million.

 

In December 2011, we initiated a restructuring plan at one of our U.S. locations which included actions to further reduce our workforce, right size capacity, and reduce operating costs. These actions were implemented to better align the business to current and expected market conditions and are expected to improve our overall cost competitiveness and increase cash flow generation. The workforce reduction primarily affected certain positions associated with our elimination of internal R&D activities.  As a result of the workforce reduction, we will be terminating the lease of one of our U.S. facilities which will result in a reduction in annual operating expenses related to this facility.  As a result of this restructuring, we recorded a restructuring charge in the DDS operating segment of $0.3 million in the fourth quarter of 2011 and $0.2 million in the second quarter of 2012.

 

Anticipated cash outflow related to the restructurings for the remainder of 2012 is approximately $1.3 million, plus any cash consideration of the Hungary lease term settlement.

 

Property and Equipment Impairment

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$     $     $ 3,967     $  

 

In the first quarter of 2012, we recorded property and equipment impairment charges of $4.0 million in our DDS segment associated with the Company’s decision to cease operations at our Budapest, Hungary facility, as discussed above.

 

Interest expense, net

 

    Three Months Ended June 30,     Six Months Ended June 30,  
(in thousands)   2012     2011     2012     2011  
                         
Interest expense   $ (116 )   $ (174 )   $ (262 )   $ (265 )
Interest income     3       91       7       143  
Interest expense, net   $ (113 )   $ (83 )   $ (255 )   $ (122 )

 

Net interest expense increased for the three and six months ended June 30, 2012 from the same period in 2011 due to increased interest rates on our interest bearing liabilities and a decrease in balances of interest bearing assets.

 

Other income (expense), net

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 136     $ (453 )   $ (656 )   $ (414 )

 

22
 

 

Other income for the three months ended June 30, 2012 was primarily due to income related to the fluctuation in exchange rates associated with foreign currency transactions. Other expense for the six months ended June 30, 2012 was primarily due to deferred financing amortization expense related to our prior credit agreement that was amended in June 2011 with a one year term.

 

Other expense for the three and six months ended June 30, 2011 was primarily due to changes in rates associated with foreign currency transactions. Other expense for the six months ended June 30, 2011 was offset in part by income from purchase accounting adjustments in the first quarter of $0.3 million related to the 2010 AMRI UK and AMRI Burlington acquisitions.

 

Income tax expense

 

Three Months Ended June 30,     Six Months Ended June 30,  
2012     2011     2012     2011  
(in thousands)  
   
$ 1,260     $ 236     $ 2,185     $ 612  

 

Income tax expense increased for the three and six months ended June 30, 2012 due primarily to the composition of pre-tax losses in relation to the applicable tax rates at our various locations worldwide.

 

23
 

 

Liquidity and Capital Resources

 

We have historically funded our business through operating cash flows and proceeds from borrowings. During the first six months of 2012, we used cash of $0.1 million in operating activities. The use of cash from operating activities includes an increase in inventory of $9.9 million. T he Company currently expects to sell this inventory during the second half of 2012 and collect the accounts receivable associated with the sale of this inventory thereafter.

 

During the first six months of 2012, cash used in investing activities was $4.5 million, resulting primarily from the acquisition of property and equipment. During the first six months of 2012, we used $2.5 million in financing activities, relating primarily to pledging $5.0 million of cash to collateralize our revolving line of credit issued in conjunction with our credit facility executed in April 2012, partially offset by net proceeds from the term loan issued under this agreement.

 

Working capital was $69.4 million at June 30, 2012 as compared to $62.6 million as of December 31, 2011.

 

In April 2012, we entered into a $20.0 million credit facility consisting of a 4-year, $5.0 million term loan and a $15.0 million revolving line of credit. As of June 30, 2012, the Company had $9.2 million of outstanding letters of credit secured by the new line of credit.

 

Borrowings under this agreement bear interest at a fluctuating rate equal to (i) in the case of the term loan, the sum of (a) an interest rate equal to daily three month LIBOR, plus (b) 3.25%; and (ii) in the case of advances under the revolving line of credit, the sum of (a) an interest rate equal to daily three month LIBOR, plus (b) 2.75%. As of June 30, 2012, the interest rate on the outstanding term loan was 3.75%.

 

The credit facility contains financial covenants, including certain net cash flow requirements for 2012, a minimum fixed charge coverage ratio commencing in 2013 and extending for the remaining term of the agreement, maximum quarterly year-to-date capital expenditures, minimum monthly domestic unrestricted cash and maximum average monthly cash reserves held at international locations. As of June 30, 2012, the Company was in compliance with its current financial covenants.

 

The disclosure of payments we have committed to make under our contractual obligations is set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” under Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. There have been no material changes to our contractual obligations since December 31, 2011, except for long term debt repayments and the April 2012 credit facility as discussed above and in Note 4 to the condensed consolidated financial statements. As of June 30, 2012, we had no off-balance sheet arrangements as defined in Item 303(a)(4) of the Securities and Exchange Commission’s Regulation S-K.

 

We continue to pursue the expansion of our operations through internal growth and strategic acquisitions. We expect that additional expansion activities will be funded from existing cash and cash equivalents, cash flow from operations and/or the issuance of debt or equity securities and borrowings. Future acquisitions, if any, could be funded with cash on hand, cash from operations, and/or the issuance of equity or debt securities. There can be no assurance that attractive acquisition opportunities will be available to us or will be available at prices and upon such other terms that are attractive to us. We regularly evaluate potential acquisitions of other businesses, products and product lines and may hold discussions regarding such potential acquisitions. As a general rule, we will publicly announce such acquisitions only after a definitive agreement has been signed. In addition, in order to meet our long-term liquidity needs or consummate future acquisitions, we may incur additional indebtedness or issue additional equity or debt securities, subject to market and other conditions. There can be no assurance that such additional financing will be available on terms acceptable to us or at all. The failure to raise the funds necessary to finance our future cash requirements or consummate future acquisitions could adversely affect our ability to pursue our strategy and could negatively affect our operations in future periods.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to inventories, goodwill, long-lived assets, pension and postretirement benefit plans, income taxes and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

24
 

 

We refer to the policies and estimates set forth in the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Estimates” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. There have been no material changes or modifications to the policies since December 31, 2011.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

There have been no material changes with respect to the information on Quantitative and Qualitative Disclosures about Market Risk appearing in Part II, Item 7A to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

As required by rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the Company’s last fiscal quarter our management conducted an evaluation with the participation of our Chief Executive Officer and Chief Financial Officer regarding the effectiveness of our disclosure controls and procedures. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management was required to apply its judgment in evaluating and implementing possible controls and procedures. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the Company’s last fiscal quarter, our disclosure controls and procedures were effective in that they provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, including ensuring that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer as appropriate to allow timely decisions regarding required disclosure. We intend to review and document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, on an ongoing basis, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the Company’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

25
 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Please refer to Part 1 – Note 10 to the condensed consolidated financial statements for further details and history on the Company’s material litigation.

 

Item 1A. Risk Factors

In addition to the other information set forth in this report, the risks and uncertainties that we believe are most important for you to consider are discussed in Part II, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2011, which could materially affect our business, financial condition or future results.

 

Item 6. Exhibits

 

  Exhibit    
  Number   Description
       
  10.1   Amended and Restated Employment Agreement, dated as of April 5, 2012, by and between the Company and Thomas E. D’Ambra, Ph.D. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012)***
       
  10.2   Amended and Restated Employment Agreement, dated as of April 5, 2012, by and between the Company and Mark T. Frost (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012)***
       
  10.3   Amended and Restated Employment Agreement, dated as of April 5, 2012, by and between the Company and Steven R. Hagen, Ph.D. (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012)***
       
  10.4   Amended and Restated Employment Agreement, dated as of April 5, 2012, by and between the Company and Bruce J. Sargent, Ph.D. (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012)***
       
  10,5   Amended and Restated Employment Agreement, dated as of April 5, 2012, by and between the Company and Lori M. Henderson (incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012)***
       
  10.6   Credit and Security Agreement dated April 11, 2012, by and among Albany Molecular Research, Inc., AMRI Rensselaer, Inc., AMRI Burlington, Inc., AMRI Bothell Research Center, Inc. and Wells Fargo Bank, National Association. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 12, 2012)
       
  31.1   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
       
  31.2   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
       
  32.1   Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
       
  32.2   Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
       
  101   XBRL (eXtensible Business Reporting Language).  The following materials from Albany Molecular Research, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, formatted in XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Equity and Comprehensive Income, (iv) the Consolidated Statements of Cash Flows and (v) notes to consolidated financial statements.**

 

26
 

 

* This certification is not “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing under the Securities Act or the Securities Exchange Act.

 

** XBRL (Extensible Business Reporting Language) information is furnished and not deemed filed or a part of a registration

statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, or section 18 of the

Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

*** Denotes management contract of compensation plan or arrangement.

 

27
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ALBANY MOLECULAR RESEARCH, INC.
     
     
Date: August 9, 2012 By: /s/ Mark T. Frost  
    Mark T. Frost
    Senior Vice President, Administration, Chief Financial Officer and Treasurer
(Duly Authorized Officer and Principal Financial Officer)

 

28

 

 

Exhibit 31.1

 

CERTIFICATION

 

I, Thomas E. D’Ambra, Ph.D. certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Albany Molecular Research, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2012 /s/ Thomas E. D’Ambra  
  Name: Thomas E. D’Ambra, Ph.D. 
  Title: President and Chief Executive Officer
  Principal Executive Officer

 

 

 

 

Exhibit 31.2

 

CERTIFICATION

 

I, Mark T. Frost certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Albany Molecular Research, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2012 /s/ Mark T. Frost  
  Name: Mark T. Frost
  Title: Senior Vice President, Administration, Chief Financial Officer
and Treasurer
  Principal Financial Officer

 

 

 

  

Exhibit 32.1

 

CERTIFICATION

 

The undersigned officer of Albany Molecular Research, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

Date: August 9, 2012  
  /s/ Thomas E. D’Ambra  
  Name: Thomas E. D’Ambra, Ph.D.
  Title: President and Chief Executive Officer

 

 

Exhibit 32.2

 

CERTIFICATION

 

The undersigned officer of Albany Molecular Research, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

Date: August 9, 2012 /s/ Mark T. Frost  
  Name: Mark T. Frost
  Title: Senior Vice President, Administration, Chief Financial Officer and Treasurer